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Background: Recent investigations in chronic myeloid leukemia (CML) have focused on the identiﬁcation
and characterization of leukemic stem cells (LSCs). These cells reside within the CD34+/CD38─/Lin─ fraction
and score positive for CD26 (dipeptidylpeptidase IV) a marker, expressed in both bone marrow (BM) and
peripheral blood (PB) samples, that discriminates CML cells from normal hematopoietic stem cells (HSCs) or
from LSCs of other myeloid neoplasms. CD26 evaluation could be a useful tool to improve the identiﬁcation of
CML LCSs by using ﬂow-cytometry assay.
Methods: CD26+ LSCs have been isolated from EDTA PB and BM samples of patients with leucocytosis sus-
pected for CML. Analysis of LSCs CML has been performed by using custom-made lyophilized pre-titrated anti-
body mixture test and control tube and a CD45+/CD34+/CD38−/CD26+ panel as a strict ﬂow cytometric gating
strategy.
Results: The expression of CD26 on CD34+/CD38− population was detectable in 211/211 PB and 84/84 BM
samples of subsequently conﬁrmed BCR-ABL+ CP-CML patients. None of the 32 samples suspicious for CML
but scoring negative for circulating CD26+ LSCs were diagnosed as CML after conventional cytogenetic and
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molecular testing. To validate our results, we checked for PB CD26+ LSCs in patients affected by other hema-
tological disorders and they all scored negative for CD26 expression.
Conclusions: We propose ﬂow cytometry evaluation of CD26 expression on PB CD34+/CD38− population as
a new rapid, reproducible, and powerful diagnostic tool for the diagnosis of CML. © 2019 The Authors. Cytometry
Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of International Clinical Cytometry Society.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloprolifera-
tive disorder characterized by increased proliferation
and accumulation of immature myeloid cells in the
peripheral blood (PB) and bone marrow (BM) of CML
patients, without the loss of their capacity to differenti-
ate. Its incidence is one to two cases per 100,000 adults
and it accounts for approximately 15% of newly diag-
nosed cases of leukemia (1,2). The increase of myeloid
precursors is due to a speciﬁc acquired genetic alteration
in the DNA of the hematopoietic stem cells (HSCs) that
behave as disease-initiating leukemic stem cells (LSCs),
gaining a proliferative advantage and/or aberrant differ-
entiation capacity over the normal counterpart to give
rise to the expanded myeloid compartment (3,4).
CML is one of the best-characterized leukemias at a
molecular level. The translocation t(9;22)(q34;q11), that
leads to the formation of the Philadelphia chromosome
(Ph) and of the BCR-ABL1 fusion protein, is found in up
to 95% of patients affected by CML, and other additional
complex rearrangements are found in 5–10% of the
remaining patients (5,6). Criteria for an appropriate CML
diagnosis consist of documenting, in the setting of per-
sistent unexplained leukocytosis, the presence of the Ph
chromosome by cytogenetic analysis, or the Ph-related
molecular BCR-ABL1 abnormalities by ﬂuorescence in
situ hybridization (FISH) or by molecular studies (7).
However, in some cases it may be difﬁcult to differenti-
ate CML from other myeloproliferative or myelodysplas-
tic syndromes that could harbor the BCR-ABL1 fusion,
and moreover, both cytogenetic and molecular analysis
are costly and require several days to be completed.
New attempts for a fast and reliable CML diagnosis
comprise the use of ﬂow cytometry for the detection of
the BCR-ABL transcript, by using antibodies able to
directly bind to the leukemic BCR-ABL1 clone (8) or by
quantifying leukocytes harboring the BCR-ABL1 fusion
at the protein level (9). Nevertheless, those methods
are time-consuming and thus could not substitute the
cytogenetic or molecular tests as routine analysis; addi-
tionally being still focused on the search of the BCR-
ABL product, they appear redundant with respect to
standard assays for CML. A step forward in the develop-
ment of a rapid CML diagnostic tool could be repre-
sented by ﬂow cytometry direct evaluation of CML
LSCs, so to overcome also the variability between CML
patients on the BCR-ABL transcript level.
In CML, LSCs supposedly reside within the CD34+/
CD38─/Lin─ fraction; however, normal HSCs also exhibit
this phenotype (10) so that additional markers are
required to discriminate CML LSC from normal HSCs
(11–13). Recent researchers have focused on the identiﬁ-
cation and characterization of LSCs, and Herrmann et al.
identiﬁed CD26 (dipeptidylpeptidase IV) as a potential
biomarker for the quantiﬁcation and isolation of CML
LSCs in BM samples of CML patients (14,15). In fact, in
contrast to other tested antigens which are co-expressed
on CML LSCs, acute myeloid leukemia (AML) LSCs, and
normal HSCs, CD26 was the only marker, expressed in
all tested bone marrow CP CML patients, which was not
present on CD34+/CD38− SC in normal BM or on LSCs
of other myeloid neoplasms. The proof of stemness of
CD34+/CD38−/CD26+ population has been demonstrated
by Hermann et al. in an NSG mice model where CD26+
cells derived from CP CML patients were capable of
inducing BCR-ABL+ engraftment (14).
The work by Culen et al. further demonstrated that
ﬂow cytometry approach could be a useful tool for the
identiﬁcation of CML LSCs on BM samples by using a
CD45+/CD34+/CD38−/CD26+ panel as a strict gating
strategy (16).
We have recently demonstrated that in CML patients
at diagnosis CD34+/CD38−/CD26+ LSCs are easily mea-
surable also in PB and that residual circulating CD26+
LSCs persist, at lower level, in most patients during
treatment with tyrosine kinase inhibitors (TKIs) and
even after successful TKI discontinuation (17). Based
on these premises, we here focus deeper on the feasi-
bility and speciﬁcity of the detection of PB CD26+ LSCs
and propose ﬂow cytometry as a new approach for a
rapid screening of any suspicious leukocytosis as well
as a reliable diagnostic tool for CML.
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MATERIALS AND METHODS
Patients Cohort
Subjects with leukocytosis suspected for CML, refer-
ring to several Italian Hematology centers, entered this
multicenter study (including 243 patients). All partici-
pating subjects provided an informed consent in accor-
dance with their referred hospital policy and agreed
upon having their blood or bone marrow assayed in
Siena Flow Cytometry Laboratory in addition to the
diagnostic tests performed locally. In order to validate
our results, patients with blood disorders other than
CML, and normal HSCs donors treated with
granulocyte-colony stimulating factors (G-CSF), were
included to participate as negative controls.
Sample Preparation
Three milliliters of EDTA PB samples (all 211 sub-
jects) or 1 mL of EDTA BM sample (only 84 subjects)
were centrally analyzed at Flow-cytometry lab in Siena
within 24 h of collection, since in preliminary experi-
ments it was shown that within 24 h cell viability was
superior to 80%. BM and PB leukocytes and red blood
cells count was performed using a Unicell DxH
800 Coulter (Beckman Coulter, Brea, CA). In all PB and
BM samples, the presence of CD34+/CD38−/CD26+
population was evaluated by multiparametric ﬂow cyto-
metry analysis using a four-color staining standardized
protocol with lyse stain wash procedure. Red cells’ lysis
was performed with BD Pharm Lyse™ ammonium
chloride (Ref 555899, BD Biosciences, San Jose, CA),
1:10 diluted in deionized water, using BD FACS™ Lyse
Wash Assistant (LWA) instrument (BD Biosciences, San
Jose, CA). After lysis, 2.0 × 106 leucocytes per mL were
incubated with a custom-made lyophilized pre-titrated
antibody mixture test and control tube (Ref 625183, BD
Biosciences, San Jose, CA), containing CD34-FITC
(clone 581), CD26-PE (clone M-A261), CD38-APC
(clone HIT2), and CD45-V500 (clone 2D1) for tube test
and CD34-FITC (clone 581), anti IGg1 PE, CD38-APC
(clone HIT2), and CD45-V500 (clone 2D1) for
control tube.
Flow Cytometry Analysis
Analysis of BM and PB samples was performed on
two 3-lasers, 8-colors BD FACSCanto™ II ﬂow cyt-
ometers using the FACSDiva 8 software version 8.0.1
BD™ (BD Biosciences, San Jose, CA) in order to reach
a sensitivity of 10−5, and the acquisition and analysis of
at least 1.0 × 106 cells. Instruments setup were moni-
tored daily and, to ensure reproducible results over
time, we followed a standardized protocol that implied
adjustments of FACS internal parameters, using the BD
FACSDiva™ CS&T IVD Beads (Ref 656047; BD Biosci-
ences, San Jose, CA), to keep constant the instrument
performance by correcting wear of lasers and ﬂuidic
instability (18). For compensation setup, BD
OneFlow™ Setup Beads (Ref 658620; BD Biosciences,
San Jose, CA) and BD™ FC Beads 8-color Kit (Ref
658621; BD Biosciences, San Jose, CA) were used. The
CD26+ population was identiﬁed by sequential gates
with the aim to exclude debris and doublets, using the
analysis procedure described and published in our pre-
vious work (16). As shown in Figure 1, ﬁrstly, the
FIG. 1. Analysis of CD26 expression in PB CD34+ fraction of suspected CML. a. CD45 versus SSC; b. Gate CD34+ cells; c. CD34+ cells display CD45
dim and SSC low; d. CD34+CD38− cells in CD34+; e. CD34+CD38− cells display CD45 dim and SSC low; f. Expression of IgG isotipic control on CD34+
CD38− gated cells; g. CD26 expression on CD34+CD38− gated cells. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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CD34 gate was performed on viable cells identiﬁed by
FSC and SSC light properties (a–b); then, exclusively
CD34+/CD38− population was gated (d). Both CD34+
and CD34+/CD38− cells display CD45dim expression
and low SSC (c–e). Figure 1f,g compare CD26 expres-
sion in control (f ) and test tube (g).
RESULTS
Evaluation of CD26+ CML LSCs
A total number of 243 patients with leukocytosis sus-
pected of CML were tested for the presence of circulat-
ing PB CD26+ LSCs. After ﬂow cytometry evaluation
211/243 samples scored positive for the presence of the
CD26 antigen and 211/211 (100%) were subsequently
conﬁrmed to be BCR-ABL1 positive by FISH and RT-
PCR. None of the 32 samples resulting negative for the
presence of CD26+ LSCs was diagnosed as CML after
conventional cytogenetic and molecular testing. In the
211 samples scoring CD26+ LSCs positive, the median
percentage of CD26+ cells within the CD34+/CD38−
stem cell fraction was 37,99% (range 1,11–99,85) and
the median absolute number of CD26+ LSCs was
10,46 × 109/L (range 0,010–1037 × 109/L) (Table 1).
Comparison of CD26+ CML LSCs Evaluation in PB versus
BM Samples
In 84/243 cases the CD34+/CD38−/CD26+ cells have
been evaluated both in BM and PB samples. The results
(Table 1) show that all BM samples of subsequently
conﬁrmed CML cases scored positive for the presence
of CD26+ LSCs. In particular, the proportion of CD26+
cells within the CD34+/CD38− cell fraction appeared to
be lower in BM than that documented in PB (median
value was 17,70%, range 5,12–98,18 vs 37,23%, range
5,59–98,57) but the absolute numbers in the BM and
PB were superimposable (median value 13,17 × 109/L,
range 0,21–365 × 109/L vs 15,54 × 109/L, range
0,06–357 × 109/L). Figure 2 compares CD26 expression
in representative PB and BM samples. These results fur-
ther conﬁrmed the appropriateness to detect but also
“quantify” LSCs directly from PB samples of CML
patients.
Validation of CD26+ CML LSCs Evaluation
As described above, 32/243 PB samples with suspi-
cion of CML scored negative for CD26+ LSCs. Most of
them (23/32, 72%) turned out to be secondary
inﬂammatory-related leukocytosis while 5/32 (16%)
were subsequently concluded as myelodysplastic/mye-
loproliferative syndromes and 4/32 (12%) as myeloﬁ-
brosis. In order to further validate our results, we
checked for PB CD26+ LSCs patients affected by other
hematological disorders such as Ph+ Acute Lymphoblas-
tic Leukemia (5 cases), Ph+ AML (2 cases), other
chronic myeloproliferative neoplasms (18 cases) and
normal HSCs donors treated with granulocyte-colony
stimulating factors G-CSF (16 cases). In all these addi-
tional cases tested, different amount of circulating
CD34+/CD38− stem cells were detected but they always
scored negative for the expression of CD26 antigen.
Eterogeneity of CML Patients Does Not Affect CD26+
Evaluation
LSCs scored positive for CD26 antigen in all newly
diagnosed CML cases, independently from the BCR-
ABL transcript type of the patients. Indeed, from a
molecular point of view, 207/211 patients had p210
BCR-ABL transcript, 3/211 had both p190 and p210
BCR-ABL transcript, while one patient had p230 tran-
script, yet all of them were positive for CD26+ LSCs.
Moreover, 60/211 patients started hydroxyurea as a
cytoreductive treatment before performing the ﬂow
cytometric analysis, but the drug seems not to affect the
CD26+ CML LSCs detection in the samples. Indeed, as
showed in Table 1, the percentage and the absolute
number of CD26+ LSCs were very similar between trea-
ted and untreated patients (median value 46,11% range
1,11–98,57 vs 37,50% range 1,33–99,85, respectively;
median value 19,2 × 109/L, range 0,02–698 × 109/L vs
8,53 × 109/L range 0,010–1037 × 109/L, respectively).
DISCUSSION
To our knowledge, this is the ﬁrst study in which the
feasibility and speciﬁcity of detecting CD26+ LSCs in PB
were investigated for diagnostic purpose in CML
patients. Recent reports have shown that CML LSCs are
Table 1
CD26 ﬂow cytometry evaluation in peripheral blood and bone marrow CML samples
Total PB PB untreated1
PB after cytoreductive
treatment2 PB3 BM3
Samples 211 151 60 84 84
% CD26+ cells within CD34+/
CD38− fraction
37,99 37,50 46,11 37,23 17,70
Median (range) (1,11–99,85) (1,33–99,85) (1,11–98,57) (5,59–98,57) (5,12–98,18)
CD26+ cells x 109/L 10,4625 8,53 19,2 15,54 13,17
Median (range) (0,010–1037) (0,010–1037) (0,02–698) (0,06–357) (0,06–357)
1Untreated patients
2Patients treated with hydroxyurea
3Comparison between PB and BM CD26 evaluation
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restricted to the CD34+/CD38− population and can be
detected in BM of patients at the onset of the disease
by co-expression of CD26 (dipeptidylpeptidase IV), an
enzyme that disrupts LSC-niche interactions by degrad-
ing SDF-1 (15). CD26 may be considered a robust spe-
ciﬁc marker of bone marrow LSCs in CML because it is
not detected on normal SC or in LSCs from other hema-
topoietic malignancies but the role of detecting PB
CD26+ LSCs as diagnostic tool for CML has not been
rule out yet (14,15).
Our results clearly demonstrate that the expression of
CD26 on CD34+CD38− population was detectable in
211/211 PB samples of subsequently conﬁrmed newly
diagnosed CP-CML patients and was also demonstrable in
84/84 CML BM aspirates. None of the 32 samples suspi-
cious for CML but scoring negative for circulating CD26+
LSCs was diagnosed as CML after conventional cytoge-
netic and molecular diagnostic workout. These results not
only conﬁrm the speciﬁcity of the expression of CD26 as
a marker of CML LSCs, but also clearly assess that this
population is a robust and reliable PB hallmark for CML,
to be assayed in a rapid, low-cost, patient-friendly, ﬂow
cytometry test to quickly rule out the suspicion of CML.
In fact, the determination of a CD34+/CD38−/CD26+
population in PB by ﬂow cytometry, using a four color
staining with lyse stain wash procedure, is a simple,
easy to perform, reliable, and accurate technique that
provides results in a very short time. Having at
disposition custom-made lyophilized pre-titrated anti-
body mixture tubes makes even easier and faster the
analysis of CML LSCs and makes possible a high stan-
dardization of laboratory procedures. Moreover, the
identiﬁcation of CD26+ LSCs retains its diagnostic value
independently from the molecular BCR-ABL transcript
of CML patients and it is to not inﬂuenced by pre-
diagnosis cytoreductive treatment of samples.
The lack of invasiveness for the patient and the rapid-
ity of the test (about 3 h from blood drawing to results)
together with its demonstrated high speciﬁcity, suggest
PB CD26+ LSCs ﬂow cytometry assay to be used as ﬁrst
line test in all cases of leukocytosis suspected for CML or
other chronic myeloproliferative disorders helping the
clinicians to better manage the patient in the short term.
In fact, if conventional cytogenetics, FISH and RT-PCR
analysis for BCR-ABL remain the gold standard assays
for the diagnosis of CML, they suffer from a longer time
of execution and results, a more relevant cost and may
not be available everywhere or at the time the patients
need to be evaluated. The possibility to easily conﬁrm
the diagnosis of CML by a simple and rapid blood test at
any time could help clinicians to better timing subse-
quent speciﬁc and more invasive assays as well as to
avoid useless and costly analysis. In the current era
where health care costs are constantly increasing, we
should forthcoming any effort to “target” also the diag-
nostic workout and to avoid waste of resources.
FIG. 2. CD26 expression in PB and BM CD34+ fraction of suspected CML. a. Expression of IgG isotipic control on PB CD34+CD38− gated cells; b,
CD26 expression on PB CD34+CD38− gated cells; c. Expression on IgG isotipic control on BM CD34+CD38− gated cells; d. Expression on BM
CD34+CD38− gated cells. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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In conclusion, our data strongly suggest that circulat-
ing CD26+ LSCs are a hallmark of CML and we propose
ﬂow cytometry evaluation of CD26 expression on PB
CD34+/CD38− population as a new powerful diagnostic
tool for the diagnosis of CML. In addition, work is in
progress to conﬁrm CD26+ LSC evaluation as an eligible
test for MRD monitoring and for the identiﬁcation of
patients suitable for TKI discontinuation.
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